Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Amgen Inc. et al v. Sandoz Inc. et al
Case Number:
3:14-cv-04741
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
February 25, 2015
Sandoz Slams Amgen's Injunction Bid In Biosimilar Suit
Sandoz Inc. on Tuesday bashed a bid by Amgen Inc. to block it from marketing its biosimilar version of Amgen's blood treatment Neupogen, saying Amgen hasn't met the requirements for the California federal court to approve its preliminary injunction bid.
-
February 06, 2015
Amgen Demands Injunction In Biosimilar Suit
Amgen Inc. asked a California federal judge on Friday to grant it a preliminary injunction in its fight with Sandoz Inc. over a biosimilar version of Neupogen, arguing that Sandoz's market entry will be illegal and will irreparably harm Amgen and that an injunction is in the public interest.
-
January 26, 2015
Sandoz Says Amgen Biosimilar Claims Conflict With ACA
Sandoz Inc. is fighting Amgen Inc.'s claims that biosimilars makers must share information with rivals and refrain from marketing copycat products for six months after winning approval, telling a California federal judge that the arguments conflict with Affordable Care Act goals.
-
January 07, 2015
Amgen Tries To Force Sandoz Biosimilar Disclosures
Amgen Inc. on Tuesday urged a California federal judge to find that Sandoz Inc. flouted the Affordable Care Act by withholding information on its biosimilar version of Neupogen, setting the stage for a decision with big implications for copycat biologics.
-
January 05, 2015
Sandoz Biosimilar Wins Support From FDA Staff
U.S. Food and Drug Administration staff on Monday recommended approval of Sandoz Inc.'s biosimilar version of Amgen Inc.'s blockbuster biologic Neupogen, a milestone that marks the first such endorsement under an Affordable Care Act pathway for lower-cost specialty drugs.
- ← Previous
- 1
- 2
- Next →